Clinical Trials Browser

Phase 2 × Urinary Bladder Neoplasms × IPI-549 × Clear all

NCT03980041 2022-11-25

Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell